Viropharma Incorporated - Consolidated Financial Statements

August 21, 2014

Shire plc (the “Company”) (LSE: SHP, NASDAQ: SHPG) is today publishing the audited consolidated financial statements for ViroPharma Incorporated, dated April 29, 2014, for the year ending December 31, 2013.

For further information please contact:

Investor Relations  
Jeff Poulton jpoulton@shire.com
+1 781 482 0945
Sarah Elton-Farr seltonfarr@shire.com
+44 1256 894157

 

Media  
Stephanie Fagansfagan@shire.com
+1 781 482 0460
Gwen Fishergfisher@shire.com
+1 484 595 9836

 

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.

We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.

www.shire.com

Click here for the PDF version of this press release.